Tyler Research Institute, LLC — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$595,944	8
2024	Research	$558,676	145
2023	Research	$286,573	95
2022	Research	$10,778	2
2020	Research	$12,637	4

Breakdown

Who paid Research payments · program years 2020–2025

Teva Pharmaceuticals USA, Inc. $1,451,971 250 payments
RedHill Biopharma Inc. $12,637 4 payments

Studies the money was for Research payments · program years 2020–2025

A 14 Week Phase 2b, Randomized, Double-Blind, Dose-Ranging Study to Determine the Pharmacokinetics, Efficacy, Safety and Tolerability of TEV-48574 in Adult Patients With Ulcerative Colitis or Crohn's Disease (RELIEVE UCCD) $857,188 200 payments
A 44-Week Phase 2b Long-Term Extension, RandomizEd, Double-BLind, Study to Determine the Long-Term PharmacokInetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult PatiEnts With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Main Phase of the Dose-Ranging Study (RELIEVE UCCD LTE) $594,783 50 payments
Open Label Efficacy and Safety of Anti-Map (Mycobacterium Avium SSP. Paratuberculosis) Therapy in Adult Crohn's Disease $11,052 1 payment
An Open Label Study to Assess the Efficacy and Safety of Fixed-Dose Combination Rhb-104 in Subjects With Active Crohn's Disease Despite 26 Weeks of Participation in the Map US Rhb-104-01 Study $1,585 3 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.